Ghazi Payam, Moffett Brady S, Cabrera Antonio G
Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Pediatr Cardiol. 2014 Jun;35(5):767-70. doi: 10.1007/s00246-013-0850-x. Epub 2013 Dec 22.
This retrospective study aimed to compare systolic and diastolic blood pressures between patients with acute kidney injury (AKI) after initiation of angiotensin-converting enzyme (ACE) inhibitor therapy and those of patients who do not experience AKI after ACE inhibitor therapy. Of 332 patients who received an ACE inhibitor as inpatients at our institution from 1 January 2010 to 1 July 2012, 20 patients had a doubling of serum creatinine (SCr) within 72 h after initiation or dose uptitration of an ACE inhibitor (AKI group). These cases were matched one to four by age and gender to patients who received an ACE inhibitor but did not have a doubling of SCr (control group). The patients in the AKI group had a significantly greater decrease in systolic and diastolic blood pressures before their AKI than the control group. Pediatric patients who experience ACE inhibitor-associated AKI have a significantly greater decrease in blood pressure than patients who do not experience ACE inhibitor-associated AKI. The authors suggest that the risk and benefits of ACE inhibitor use be stringently evaluated before initiation of therapy.
这项回顾性研究旨在比较血管紧张素转换酶(ACE)抑制剂治疗开始后发生急性肾损伤(AKI)的患者与ACE抑制剂治疗后未发生AKI的患者的收缩压和舒张压。在2010年1月1日至2012年7月1日期间于我院住院接受ACE抑制剂治疗的332例患者中,20例患者在ACE抑制剂开始使用或剂量上调后72小时内血清肌酐(SCr)翻倍(AKI组)。这些病例按年龄和性别与接受ACE抑制剂但SCr未翻倍的患者以1:4的比例进行匹配(对照组)。AKI组患者在发生AKI之前收缩压和舒张压的下降幅度明显大于对照组。发生ACE抑制剂相关AKI的儿科患者血压下降幅度明显大于未发生ACE抑制剂相关AKI的患者。作者建议在开始治疗前应严格评估使用ACE抑制剂的风险和益处。